The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Dec 2016 14:38

RNS Number : 1109T
Motif Bio PLC
30 December 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Motif Bio plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

 

Amphion Innovations plc

 

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

29/12/2016

 

6. Date on which issuer notified:

29/12/2016

7. Threshold(s) that is/are crossed orreached: vi, vii

16%, 17%, 18%, 19%, 20%, 21%, 22%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct,

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00BVVT4H71

28,729,875

28,729,875

43,240,645

43,240,645

22.09%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

43,240,645

22.09%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

 

14. Contact name:

Charlie Morgan

15. Contact telephone number:

+1 (212) 210 6224

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFVSFSLIVIR
Date   Source Headline
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied
20th Jul 20157:00 amRNSExercise of Options
17th Jul 20157:00 amRNSFDA QIDP Designation for Iclaprim for HABP
15th Jul 20157:00 amRNSNew Addition to Scientific Advisory Board
10th Jul 20153:29 pmRNSExercise of Options
10th Jul 20151:37 pmRNSResult of General Meeting
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPlacing to raise £22 million and Change of Adviser
9th Jun 20157:00 amRNSAudited Non-Statutory Financial Statements
4th Jun 20154:41 pmRNSSecond Price Monitoring Extn
4th Jun 20154:35 pmRNSPrice Monitoring Extension
1st Jun 20157:00 amRNSMotif partners with Leading Global CRO
28th May 20157:00 amRNSFDA Meeting Minutes Confirming Iclaprim Phase III
12th May 20157:01 amRNSMOTIF SELECTED TO PRESENT AT BIOTECH EVENT
7th May 20157:00 amRNSFunding Strategy Update
15th Apr 20157:01 amRNSFDA Results
15th Apr 20157:00 amRNSFDA agree to enter clinical development programme
2nd Apr 20157:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.